Ibudilast
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
IC50: 54-239 nM
Ibudilast is an inhibitor of PDE4.
Phosphodiesterases (PDEs) are critical inflammation and wound healing modulators. Specific targeting of PDEs for the treatment of various diseases, such as chronic obstructive pulmonary disease (COPD), has been investigated.
In vitro: Ibudilast could potently inhibit purified human PDE4A, 4B, 4C and 4D with IC50 values at 54, 65, 239 and 166 nM, respectively. Ibudilast was also able to effectively block LPS-induced tumor necrosis factor and N-formyl-MetLeu-Phe-induced leukotriene B4 biosynthesis in human whole blood [1].
In vivo: Rats received a daily oral administration of 10, 30 or 60 mg/kg ibudilast. Results showed that in the vehicle-treated animals, white matter lesions and microglial activation occurred in the optic tract, internal capsule and corpus callosum. A low dose of ibudilast failed to suppress the white matter lesions and microglial activation, whereas a dose of either 30 or 60 mg/kg ibudilast ameliorated these lesions [2].
Clinical trial: Ibudilast was studied in 13 asthmatics for its effect on airway hypersensitivity to histamine inhalation. The PC20 values improved significantly following the initial treatment with ibudilast. In addition, the severity of the attacks decreased significantly. Improvements in the PC20 and asthmatic symptoms also were observed in the disodium chromoglycate group, but these were equal to or lesser than those in the ibudilast group [3].
References:
[1] Huang, Z. ,Liu, S.,Zhang, L., et al. Preferential inhibition of human phosphodiesterase 4 by ibudilast. Life Sciences 78(23), 2663-2668 (2006).
[2] Wakita H, Tomimoto H, Akiguchi I, Lin JX, Ihara M, Ohtani R, Shibata M. Ibudilast, a phosphodiesterase inhibitor, protects against white matter damage under chronic cerebral hypoperfusion in the rat. Brain Res. 2003 Nov 28;992(1):53-9.
[3] Kawasaki A, Hoshino K, Osaki R, Mizushima Y, Yano S. Effect of ibudilast: a novel antiasthmatic agent, on airway hypersensitivity in bronchial asthma. J Asthma. 1992;29(4):245-52.
Physical Appearance | A crystalline solid |
Storage | Store at -20°C |
M.Wt | 230.3 |
Cas No. | 50847-11-5 |
Formula | C14H18N2O |
Synonyms | AV 411,KC-404 |
Solubility | insoluble in H2O; ≥32 mg/mL in EtOH; ≥46.7 mg/mL in DMSO |
Chemical Name | 2-methyl-1-[2-(1-methylethyl)pyrazolo[1,5-a]pyridin-3-yl]-1-propanone |
SDF | Download SDF |
Canonical SMILES | CC(C)C1=NN(C=CC=C2)C2=C1C(C(C)C)=O |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
质量控制和MSDS
- 批次: